897 related articles for article (PubMed ID: 16203817)
21. Flai (fludarabine, cytarabine, idarubicin) plus low-dose Gemtuzumab Ozogamicin as induction therapy in CD33-positive AML: Final results and long term outcome of a phase II multicenter clinical trial.
Candoni A; Papayannidis C; Martinelli G; Simeone E; Gottardi M; Iacobucci I; Gherlinzoni F; Visani G; Baccarani M; Fanin R
Am J Hematol; 2018 May; 93(5):655-663. PubMed ID: 29396857
[TBL] [Abstract][Full Text] [Related]
22. Phase I trial of gemtuzumab ozogamicin in intensive combination chemotherapy for relapsed or refractory adult acute myeloid leukemia (AML): Japan Adult Leukemia Study Group (JALSG)-AML206 study.
Usui N; Takeshita A; Nakaseko C; Dobashi N; Fujita H; Kiyoi H; Kobayashi Y; Sakura T; Yahagi Y; Shigeno K; Ohwada C; Miyazaki Y; Ohtake S; Miyawaki S; Naoe T; Ohnishi K;
Cancer Sci; 2011 Jul; 102(7):1358-65. PubMed ID: 21585619
[TBL] [Abstract][Full Text] [Related]
23. Gemtuzumab ozogamicin: promise and challenge in patients with acute myeloid leukemia.
Giles FJ
Expert Rev Anticancer Ther; 2002 Dec; 2(6):630-40. PubMed ID: 12503209
[TBL] [Abstract][Full Text] [Related]
24. Long-term disease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33(+) primary resistant or relapsed acute myeloid leukemia.
Chevallier P; Delaunay J; Turlure P; Pigneux A; Hunault M; Garand R; Guillaume T; Avet-Loiseau H; Dmytruk N; Girault S; Milpied N; Ifrah N; Mohty M; Harousseau JL
J Clin Oncol; 2008 Nov; 26(32):5192-7. PubMed ID: 18854573
[TBL] [Abstract][Full Text] [Related]
25. [The role of gemtuzumab ozogamicin in the treatment of acute myeloid leukemia patients].
Sakamaki H
Gan To Kagaku Ryoho; 2008 Sep; 35(9):1629-34. PubMed ID: 18799927
[TBL] [Abstract][Full Text] [Related]
26. Gemtuzumab ozogamicin.
McGavin JK; Spencer CM
Drugs; 2001; 61(9):1317-22; discussion 1323-4. PubMed ID: 11511025
[TBL] [Abstract][Full Text] [Related]
27. [Long-term complete remission after single therapy with gemtuzumab ozogamicin for refractory AML in an elderly patient].
Ogura K; Machida T; Nara M; Mayama K; Akagi T; Kubo K
Gan To Kagaku Ryoho; 2007 Nov; 34(11):1881-3. PubMed ID: 18030030
[TBL] [Abstract][Full Text] [Related]
28. Coding polymorphisms in CD33 and response to gemtuzumab ozogamicin in pediatric patients with AML: a pilot study.
Lamba JK; Pounds S; Cao X; Downing JR; Campana D; Ribeiro RC; Pui CH; Rubnitz JE
Leukemia; 2009 Feb; 23(2):402-4. PubMed ID: 18615103
[TBL] [Abstract][Full Text] [Related]
29. [Therapeutic advances in neoplastic hematology: target therapy anti-CD33].
Di Rocco A; Finolezzi E; Anaclerico B; Calabrese E; Levi A; Trasarti S; Tafuri A
Clin Ter; 2005; 156(4):183-6. PubMed ID: 16342520
[TBL] [Abstract][Full Text] [Related]
30. Simultaneously targeting CD45 significantly increases cytotoxicity of the anti-CD33 immunoconjugate, gemtuzumab ozogamicin, against acute myeloid leukemia (AML) cells and improves survival of mice bearing human AML xenografts.
Walter RB; Boyle KM; Appelbaum FR; Bernstein ID; Pagel JM
Blood; 2008 May; 111(9):4813-6. PubMed ID: 18326813
[TBL] [Abstract][Full Text] [Related]
31. Comparison of a fludarabine and melphalan combination-based reduced toxicity conditioning with myeloablative conditioning by radiation and/or busulfan in acute myeloid leukemia in Japanese children and adolescents.
Ishida H; Adachi S; Hasegawa D; Okamoto Y; Goto H; Inagaki J; Inoue M; Koh K; Yabe H; Kawa K; Kato K; Atsuta Y; Kudo K
Pediatr Blood Cancer; 2015 May; 62(5):883-9. PubMed ID: 25545836
[TBL] [Abstract][Full Text] [Related]
32. Phase I/II study of humanized anti-CD33 antibody conjugated with calicheamicin, gemtuzumab ozogamicin, in relapsed or refractory acute myeloid leukemia: final results of Japanese multicenter cooperative study.
Kobayashi Y; Tobinai K; Takeshita A; Naito K; Asai O; Dobashi N; Furusawa S; Saito K; Mitani K; Morishima Y; Ogura M; Yoshiba F; Hotta T; Bessho M; Matsuda S; Takeuchi J; Miyawaki S; Naoe T; Usui N; Ohno R
Int J Hematol; 2009 May; 89(4):460-469. PubMed ID: 19360457
[TBL] [Abstract][Full Text] [Related]
33. Gemtuzumab ozogamicin: first clinical experiences in children with relapsed/refractory acute myeloid leukemia treated on compassionate-use basis.
Zwaan CM; Reinhardt D; Corbacioglu S; van Wering ER; Bökkerink JP; Tissing WJ; Samuelsson U; Feingold J; Creutzig U; Kaspers GJ
Blood; 2003 May; 101(10):3868-71. PubMed ID: 12543868
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetics of gemtuzumab ozogamicin, an antibody-targeted chemotherapy agent for the treatment of patients with acute myeloid leukemia in first relapse.
Dowell JA; Korth-Bradley J; Liu H; King SP; Berger MS
J Clin Pharmacol; 2001 Nov; 41(11):1206-14. PubMed ID: 11697753
[TBL] [Abstract][Full Text] [Related]
35. Fractionated gemtuzumab ozogamicin combined with intermediate-dose cytarabine and daunorubicin as salvage therapy in very high-risk AML patients: a bridge to reduced intensity conditioning transplant?
Paubelle E; Ducastelle-Leprêtre S; Labussière-Wallet H; Nicolini FE; Barraco F; Plesa A; Salles G; Wattel E; Thomas X
Ann Hematol; 2017 Mar; 96(3):363-371. PubMed ID: 28011984
[TBL] [Abstract][Full Text] [Related]
36. AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: a report from the Children's Oncology Group.
Cooper TM; Franklin J; Gerbing RB; Alonzo TA; Hurwitz C; Raimondi SC; Hirsch B; Smith FO; Mathew P; Arceci RJ; Feusner J; Iannone R; Lavey RS; Meshinchi S; Gamis A
Cancer; 2012 Feb; 118(3):761-9. PubMed ID: 21766293
[TBL] [Abstract][Full Text] [Related]
37. The role of gemtuzumab ozogamicin in acute leukaemia therapy.
Tsimberidou AM; Giles FJ; Estey E; O'Brien S; Keating MJ; Kantarjian HM
Br J Haematol; 2006 Feb; 132(4):398-409. PubMed ID: 16412015
[TBL] [Abstract][Full Text] [Related]
38. Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia.
Chen YB; Coughlin E; Kennedy KF; Alyea EP; Armand P; Attar EC; Ballen KK; Cutler C; Dey BR; Koreth J; McAfee SL; Spitzer TR; Antin JH; Soiffer RJ; Ho VT
Biol Blood Marrow Transplant; 2013 Jun; 19(6):981-7. PubMed ID: 23562738
[TBL] [Abstract][Full Text] [Related]
39. Dose-related efficacy and toxicity of gemtuzumab ozogamicin in pediatric acute myeloid leukemia.
Parigger J; Zwaan CM; Reinhardt D; Kaspers GJ
Expert Rev Anticancer Ther; 2016; 16(2):137-46. PubMed ID: 26646091
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of fractionated gemtuzumab ozogamicin combined with cytarabine in advanced childhood myeloid leukaemia.
Brethon B; Yakouben K; Oudot C; Boutard P; Bruno B; Jérome C; Nelken B; de Lumley L; Bertrand Y; Dalle JH; Chevret S; Leblanc T; Baruchel A
Br J Haematol; 2008 Nov; 143(4):541-7. PubMed ID: 18759760
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
